NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your ICON Public Limited Company (NASDAQ:ICLR) investment and want ...

If you suffered losses exceeding $75,000 in ICON between July 27, 2023 and October 23, 2024 and would like to discuss your ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected ...

While a federal judge has paused the funding cuts, the uncertainty has researchers concerned about the future of scientific ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ICON plc ("ICON" or the "Company") (NASDAQ: ICLR) ordinary shares between July ...

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands against other AI news and ratings too important to miss. Artificial intelligence is rapidly ...

ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...

We recently published a list of 10 AI News and Ratings Too Important to Miss. In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands against other AI ...